注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
SQZ Biotechnologies Co是一家臨床階段的生物技術公司,專注於釋放細胞療法的全部潛力,使患有癌症、自身免疫性疾病和傳染病以及其他嚴重疾病的患者受益。在腫瘤學領域,它正在開發基於通過工程化抗原呈遞引導腫瘤抗原特異性免疫激活的細胞治療平台。它在其SQZ抗原呈遞細胞(APC)、SQZ增強型APC(eAPC)和SQZ激活抗原載體(AAC)細胞治療平台擁有三個腫瘤候選藥物。在其自身免疫性疾病產品組合中,該公司正在開發其SQZ耐受抗原載體(TAC)細胞治療平台,以恢復對自身抗原或其他自身免疫性疾病相關抗原的免疫耐受性。這些抗原是疾病發病機制的核心。APC平台主要產生CD8+ T細胞反應。SQZAPC通過對患者自身外周血單個核細胞進行體外工程改造而成。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Bernard Coulie | 56 | 2021 | Independent Chairman |
Robert S. Langer | 75 | - | Co-Founder & Member of Scientific Advisory Board |
Howard Bernstein | 67 | 2015 | Interim CEO & Director |
Klavs F. Jensen | 71 | 2013 | Independent Director |
Amy W. Schulman | 63 | 2015 | Director |
Ulrich von Andrian | - | - | Member of Scientific Advisory Board |
Darrell J. Irvine | - | - | Member of Scientific Advisory Board |
Arlene Sharpe | - | - | Member of Scientific Advisory Board |
Sapna Srivastava | 53 | 2020 | Independent Director |
Marc Schegerin | 48 | 2020 | Independent Director |
Tyler E. Jacks | 63 | - | Member of Scientific Advisory Board |
Kai W. Wucherpfennig | - | 2020 | Member of Scientific Advisory Board |
David H. Sachs | 82 | - | Member of Scientific Advisory Board |
Mark Shlomchik | - | - | Member of Scientific Advisory Board |
Marc William Elia | 48 | 2018 | Independent Director |
Pushkal P. Garg | 56 | 2018 | Independent Director |
Patrick V. J. J. Vink | 61 | 2021 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核